Basic Information
LncRNA/CircRNA Name | NORAD |
Synonyms | NA |
Region | GRCh38_20:36045622-36050960 |
Ensemble | ENSG00000260032 |
Refseq | NR_027451 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | non small cell lung cancer |
ICD-0-3 | C34 |
Methods | qPCR, Western blot, Luciferase reporter assay |
Sample | HBE, a normal bronchial epithelial cell line, and SPC-A1, H460, H1650, and A549, NSCLC cell lines, NSCLC and NSCLC-adjacent tissue |
Expression Pattern | up-regulated |
Function Description | The lncRNA NORAD expression level in NSCLC patients was notably higher than that in people in control group, that in patients with metastasis was higher than that in patients without metastasis, and that in patients with NSCLC in stage III- IV was significantly higher than that in patients with NSCLC in stage I-II. Elevation of NORAD stimulated the proliferation and migration of NSCLC A549/H460 cells. According to the reporter gene assay, NORAD could bind to miR-656-3p. Besides, miR-656-3p was significantly under-expressed in cancer tissues of patients with NSCLC, and overexpression of miR-656-3p could block the proliferation and migration of A549/H460 cells and reversed promotion on cell proliferation and migration by NORAD. Furthermore, the reporter gene assay revealed that the overexpression of AKT1, a miR-656-3p target gene, could reverse miR-656-3p's inhibitory effect on the proliferation and migration of A549/H460 cells |
Pubmed ID | 31207175 |
Year | 2019 |
Title | Long non-coding RNA NORAD promotes the occurrence and development of non small cell lung cancer by adsorbing MiR-656-3p |
External Links
Links for NORAD | GenBank HGNC NONCODE |
Links for non small cell lung cancer | OMIM COSMIC |